US 7,479,371 B2Granted

Method of judging leukemia, pre-leukemia or aleukemic malignant blood disease and diagnostic therefor

AssigneesTokai University, Kyowa Hakko Kogyo Co., Ltd., Kyowa Medex Co., Ltd.

InventorsKiyoshi Ando, Tomomitsu Hotta, Chie Ito, Hidenao Sato, Akiko Furuya, Kenya Shitara, Seiji Sugimoto, Hiroaki Kohno

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The present invention relates to a method for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases, a method of discriminating leukemia from pre-leukemia or aleukemic malignant blood diseases, a method of discriminating aplastic anemia from myelodysplastic syndrome, a method of diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells, and a method of diagnosing the graft versus host disease, each of said methods comprising quantifying stem cell growth factor (SCGF). The present invention also makes it possible to provide an agent for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases and an agent for diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells or an agent for diagnosing graft versus host disease (GVHD), each containing as an active ingredient an antibody reacting with stem cell growth factor (SCGF).

Claims14

Dependent claims

A method for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases wherein stem cell growth factor (SCGF) in an in-vivo sample is quantified, wherein the method comprises:

obtaining an in-vivo patient sample from a patient suspected of having leukemia, pre-leukemia or aleukemic malignant blood disease;
contacting the patient sample with one or more anti-SCGF antibodies;
detecting and/or quantifying SCGF present in the patient sample in an immunological assay;
thereby obtaining a patient sample SCGF value;
comparing the patient sample SCGF value to a SCGF cut-off value;
wherein the SCGF cut-off value is set based on one or more individuals that do not have leukemia, pre-leukemia, or alenkemic malignant blood disease;
and
diagnosing leukemia, pre-leukemia or aleukemic malignant blood disease if the patient sample SCGF value is above the SCGF cut-off value;
wherein the leukemia is acute lymphocytic leukemia (ALL), acute mycloid leukemia (AML), or chronic myeloid leukemia (CML), and the pre-leukemia is myelodysplastic syndrome (MDS), and the aleukemic malignant blood disease is non-Hodgkin's lymphoma (NHL) or multiple mycloma (MM).

6 more elements

Dependencies are inferred from the claim text.